EMA's transparency seems to be opaque

The Lancet

Volumn 384, Issue 9957, 2014, Pages 1847-

  Banzi, Rita ^a   Bertele, Vittorio ^a   Garattini, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN MEDICINES AGENCY; HUMAN; INFORMED CONSENT; LETTER; MEDICAL RESEARCH; PATENT; PRIORITY JOURNAL; PUBLIC HEALTH; ACCESS TO INFORMATION; CONFLICT OF INTEREST; DRUG APPROVAL; DRUG INDUSTRY; EUROPEAN UNION; MANAGEMENT;

ACCESS TO INFORMATION; CONFLICT OF INTEREST; DRUG APPROVAL; DRUG INDUSTRY; EUROPEAN UNION; HUMANS; POLICY MAKING;

EID: 84925014213     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62241-8     Document Type: Letter

References (3)

1. European Medicines Agency. European Medicines Agency policy on publication of clinical data for medicinal products for human use. 2014. www.ema.europa.eu/docs/en-GB/document-library/Other/2014/10/WC500174796.pdf (accessed Oct. 11, 2014).
2. European Medicines Agency. Draft policy 70: publication and access to clinical trial data. June 2013. www.ema.europa.eu/docs/en-GB/document-library/Other/2013/06/WC500144730.pdf (accessed Oct. 11, 2014).
3. Banzi R, Bertele' V, Demotes-Mainard J, et al. Fostering EMA's transparency policy. Eur J Intern Med 2014;25:681-84.